Good practice in the postmarketing surveillance of medicines

被引：11

作者：

Meyboom, RHB

机构：

[1] Netherlands Pharmacovigilance F., LAREB, 5026 RH Tilburg

来源：

PHARMACY WORLD & SCIENCE | 1997年 / 19卷 / 04期

关键词：

postmarketing surveillance; pharmacovigilance; adverse drug reactions; good practice; medical ethics;

D O I：

10.1023/A:1008610722972

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

in addition to Good Clinical Trial Practice for the study of experimental drugs, regulations are also needed for good practice in the assessment of medicines after approval (Good PM Practice, GPP). GPP has to protect the Interests of public health at large as well as those of individual patients, investigators and pharmaceutical companies. GPP may be natural way to solve threatening conflicts between privacy legislation and the public interest.

引用

页码：186 / 190

页数：5